Nurix Therapeutics Inc’s filing revealed that its Chief Financial Officer van Houte Hans unloaded Company’s shares for reported $84388.0 on Mar 03 ’25. In the deal valued at $14.49 per share,5,825 shares were sold. As a result of this transaction, van Houte Hans now holds 33,724 shares worth roughly $0.47 million.
Then, JOHANNES VAN HOUTE bought 5,825 shares, generating $89,996 in total proceeds.
Before that, Ring Christine sold 5,760 shares. Nurix Therapeutics Inc shares valued at $114,934 were divested by the Chief Legal Officer at a price of $19.95 per share. As a result of the transaction, Ring Christine now holds 32,538 shares, worth roughly $0.45 million.
Leerink Partners initiated its Nurix Therapeutics Inc [NRIX] rating to a Market perform in a research note published on March 17, 2025; the price target was $16. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. BMO Capital Markets began covering NRIX with “an Outperform” recommendation on December 06, 2024. UBS started covering the stock on October 24, 2024. It rated NRIX as “a Buy”.
Price Performance Review of NRIX
On Monday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock jump 2.50% to $13.93. Over the last five days, the stock has gained 2.50%. Nurix Therapeutics Inc shares have fallen nearly -26.06% since the year began. Nevertheless, the stocks have fallen -3.80% over the past one year. While a 52-week high of $29.56 was reached on 01/27/25, a 52-week low of $11.90 was recorded on 03/13/25. SMA at 50 days reached $17.48, while 200 days put it at $20.89.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 13.33, which if violated will result in even more drops to 12.72. On the upside, there is a resistance level at 14.25. A further resistance level may holdings at 14.56. The Relative Strength Index (RSI) on the 14-day chart is 37.13, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.78, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.96%. Stochastics %K at 13.69% indicates the stock is a buying.
How much short interest is there in Nurix Therapeutics Inc?
A steep rise in short interest was recorded in Nurix Therapeutics Inc stocks on 2025-02-28, growing by 0.65 million shares to a total of 11.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 10.95 million shares. There was a rise of 5.59%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $41 price target.
